Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Current Liabilities (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Total Current Liabilities for 12 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 27.81% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2025, up 27.81% year-over-year, with the annual reading at $6.6 million for FY2025, 27.81% up from the prior year.
  • Total Current Liabilities hit $6.6 million in Q4 2025 for vTv Therapeutics, down from $10.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $12.7 million in Q1 2022 to a low of $4.3 million in Q1 2025.
  • Historically, Total Current Liabilities has averaged $7.7 million across 5 years, with a median of $7.6 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: plummeted 56.88% in 2021 and later surged 146.03% in 2022.
  • Year by year, Total Current Liabilities stood at $8.5 million in 2021, then fell by 9.3% to $7.7 million in 2022, then soared by 37.77% to $10.6 million in 2023, then plummeted by 51.07% to $5.2 million in 2024, then rose by 27.81% to $6.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for VTVT at $6.6 million in Q4 2025, $10.2 million in Q3 2025, and $5.3 million in Q2 2025.